tbuckley/cabot-search huggingface dataset:
Abstract 5337: Phase 1 study of bavituximab in advanced solid tumor malignancies: Final results
Authors: Nuhad Ibrahim, Lucas Wong, Alison Stopeck, Lee S. Rosen, David E. Gerber, Joseph S. Shan
Journal: Cancer Research (2010)

Abstract Background: Bavituximab, a novel human chimeric IgG1 monoclonal antibody which targets the membrane phospholipids, phosphatidylserine complexed with β2-glycoprotein I on tumor vasculature, produces host effector cell-mediated destruction of tumor vasculature and enhancement of anti-tumor immunity (He et. al. Clin Cancer Res 2009). We are reporting on an open label dose escalation Phase 1 trial to examine the safety, pharmacokinetics and pharmacodynamics of bavituximab in adults with refractory advanced solid tumor malignancies. Methods: Patients received bavituximab monotherapy, intravenously, up to 4 doses of either 0.1, 0.3., 1 or 3 mg/kg. 26 patients with a median age of 57.6 yrs (range of 37-80 yrs) who had metastatic breast cancer (n=13), colorectal cancer (n=4), pancreatic cancer (n=3), or other solid tumors (n=6), were treated with a total of 86 doses of bavituximab. Results: 6 serious adverse events were observed in 5 patients, with 1 drug-related SAE (pulmonary embolism) at the 3 mg/kg dose. The most common AEs seen in ≥15% of patients were: nausea, fatigue; headache, constipation, dizziness cough, dyspnea, anemia, and chest pain. Pharmacokinetic measures indicated T1/2 of bavituximab ranged from 28 to 47 hrs, and Cmax on Day 0 ranged from 2 to 56 ug/ml with no accumulation seen following multiple dose administration. Coagulation testing revealed no platelet or factor abnormalities, D-dimer levels were elevated in the majority of patients at baseline and increased with disease progression. The presence of a lupus anticoagulant-like activity (prolonged aPTT or DRVVT-an in vitro test artifact) was observed only in patients treated at the highest dose tested of 3 mg/kg. Overall, 8/26 patients showed stable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) (4/14 subjects at 0.1 and 0.3 mg/kg and 4/12 subjects in 1 and 3 mg/kg dose groups). Conclusions: Bavituximab was safe and well tolerated when given as monotherapy. Based on pharmcokinetics, the maximum recommended dose for Phase II trials will be weekly at 3 mg/kg, intravenously. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5337.
Paging Dr. Google: Parents’ Report of Internet Use for Type 1 Diabetes Management
Authors: Amanda M. Balkhi, Brian Olsen, Lacie Lazaroe, Janet Silverstein, Gary R. Geffken
Journal: Diabetes Care (2015)

Caregivers are important for effective treatment management of a child’s type 1 diabetes, as effective treatment often requires intensive care. Some parents balance this high burden of care by turning to the Internet for additional information (online health information seeking [OHIS]) and often use information found online to care for their child (1,2). This is potentially concerning as the quality and accuracy of online health information are variable (3,4); however, reliable estimates of OHIS have not been established. The current study will examine the prevalence and frequency of OHIS in type 1 diabetes caregivers.

The researchers designed a brief survey for caregivers to complete while waiting for their child’s appointment at a large Southeastern pediatric diabetes specialty clinic. The survey assessed parents’ demographics and their use of online sources for diabetes information. A total of 49% …
A polymorphism of the ability to smell urinary metabolites of asparagus.
Authors: M Lison, S H Blondheim, R N Melmed
Journal: BMJ (1980)

The urinary excretion of (an) odorous substance(s) after eating asparagus is not an inborn error of metabolism as has been supposed. The detection of the odour constitutes a specific smell hypersensitivity. Those who could smell the odour in their own urine could all smell it in the urine of anyone who had eaten asparagus, whether or not that person was able to smell it himself. Thresholds for detecting the odour appeared to be bimodal in distribution, with 10% of 307 subjects tested able to smell it at high dilutions, suggesting a genetically determined specific hypersensitivity.
On a Peculiar Kind of Hare-Lip; and its Treatment
Authors: K. King
Journal: BMJ (1873)

rApril 5, I873.predispositioni to brain-disease, though the particular form wlhich might appear would be altogether uncertain.Nobody doubts, however, that quasi-pathological accidents may determine in another inidividual, who inherits no such predisposition, similar forms of disease.The case is preciselv the same with regard to lung-diseases.A man may inherit from his ancestors lungs which contain within themselves the elements of weakness-organs the tissues of which are so constituted, with relation to the whole organism, that the very slightest determing causes suffice to initiate a set of changes which terminate in one or other of the forms of pulmonary phthisis.And, similarly, just as brain-disease may be acquired in the life of an individual who inherits no predis- position, so, under the stronger pressure of general and local causes, may any of the forms of phthisis manifest themselves in individuals who inherit no family predisposition to such a disease.Where is the difficulty?What occasion have we to resort to the use of the word "tubercle"?How does so much depend upon the use we make of it ?I must confess myself unable to understand what Dr.Wilson Fox means when he says: " The etiology of phthisis, the therapeutics of phthisis, and the prognosis of phthisis, all hang upon this point-how far tubercle is concerned in the morbid anatomy of phthisis."To me it seems quite the reverse.I regard this question as one of a mere verbal nature, and as capable of being separated entirely from all problems as to the etiology, therapeutics, and pro- gnosis of phthisis.
Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154
Authors: H. Xu
Journal: Journal of Clinical Investigation (2006)

CD154 is a cell surface molecule expressed on activated T cells that binds to CD40, an activating molecule on APCs. Its blockade has been shown to prevent allograft rejection, presumably by interrupting interactions between T cells and APCs. It is known that activated human platelets express and shed CD154 and can induce APC activation and other immune processes in vitro. Here we show that platelet-derived CD154 is sufficient to initiate cardiac allograft rejection independent of any cellular source of this molecule. CD154-KO mice reject cardiac allografts after receiving CD154-expressing human platelets or recombinant CD154 (rCD154) trimers. Treatment with the human CD154-specific mAb 5c8 specifically prevents this induced rejection. Soluble trimers, but not platelets, induce rejection when infused temporally remote from the surgical procedure, suggesting that surgically induced platelet activation is required for CD154 release. Allograft rejection can thus be instigated by activated platelets through CD154. These data implicate platelets as a proximal component of acquired alloimmunity, providing insight into the mechanisms of allograft rejection and the physiological response to trauma in general.
The Development and Validation of an Outcome Measure for Spiritual Healing: A Mixed Methods Study
Authors: Felicity L. Bishop, Fiona Barlow, Jan Walker, Clare McDermott, George T. Lewith
Journal: Psychotherapy and Psychosomatics (2010)

&lt;i&gt;Background:&lt;/i&gt; Spiritual healing, probably the oldest documented paramedical intervention, is a neglected area of research. In order to conduct further research into the effects of healing, a valid and reliable outcome measure is needed that captures the experience of individuals receiving healing (healees) and is not burdensome to complete. We aimed to develop such a measure. &lt;i&gt;Methods:&lt;/i&gt; A mixed methods design was used. Focus groups and cognitive interviews were used to generate and refine questionnaire items grounded in the experiences and language of healees (Study 1). The resulting questionnaire was tested and its formal psychometric properties were evaluated (Study 2). Participants were recruited from a spiritual healing sanctuary and via individual healers (including registered spiritual healers, Reiki practitioners, healers affiliated with churches). &lt;i&gt;Results:&lt;/i&gt; In Study 1, 24 participants took part in 7 focus groups and 6 cognitive interviews. 29 common effects were identified and grouped into 7 discrete dimensions that appeared to characterize potentially sustainable effects reported by participants following their experiences of spiritual healing. In Study 2, 393 participants returned completed baseline questionnaires, 243 of whom completed the questionnaire again 1–6 weeks later. Exploratory factor analysis generated 5 subscales, based on 20 of the items: outlook, energy, health, relationships and emotional balance. These subscales demonstrated acceptable internal consistency, convergent validity and test-retest reliability. Three of the subscales and the whole questionnaire demonstrated good sensitivity to change. &lt;i&gt;Conclusions:&lt;/i&gt; We have produced a psychometrically sound healing impact questionnaire that is acceptable to healees, healers and researchers for use in future evaluations of spiritual healing.
COMPARISON OF OSTIAL AND CROSSOVER DRUG-ELUTING STENT IMPLANTATION TECHNIQUE FOR MEDINA (0,1,0) OR (0,0,1) BIFURCATED LESION
Authors: Yasunari Sakamoto, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Tsuyoshi Sakai, Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano, Masahiro Yamawaki, Tamon Kato, Hideyuki Takimura, Ikki Komatsu, Takuro Takama
Journal: Journal of the American College of Cardiology (2012)
Altered Biodistribution of Ga-67 Citrate in an Iron-Overloaded Patient With Sickle Cell Disease
Authors: ANDREW C. LOESBERG, WILLIAM B. MARTIN
Journal: Clinical Nuclear Medicine (1994)

The biodistribution of Ga-67 citrate can be altered by a number of pharmaceuticals, treatments, and interventions. The authors present a case of a 19-year-old black man with sickle cell disease who received a Ga-67 scan to evaluate for possible left leg osteomyelitis. The patient received multiple blood transfusions over several years due to refractory anemia, causing an unusual distribution of Ga-67 activity.
Reply to M. Marignani et al
Authors: Nozomi Niitsu
Journal: Journal of Clinical Oncology (2011)

We appreciate the comments raised in the correspondence from Marignani et al regarding our recently published article. The cost-effectiveness profile is thought to be an important issue. However, the ultimate goal is to be able to safely administer rituximab combination chemotherapy to patients who are positive for the hepatitis B surface antibody (anti-HBs) and/or hepatitis B core antibody and to cure the lymphoma. Therefore, a study is necessary to determine whether an antiviral drug should be given to these patients as prophylaxis before starting rituximab combination chemotherapy or after HBV-DNA is detected. In our study, among the patients positive for anti-HBs and/or hepatitis B core antibody who were receiving rituximab combination chemotherapy, entecavir was started when HBV-DNA was detected ( 1.8 log copies), and rituximab combination chemotherapy was continued. The outcome of treatment for lymphoma in these patients was good. With respect to whether lamivudine or entecavir should be administered, with lamivudine (cost of ¥683/d in Japan), HBV-resistant mutants appear in 20% to 30% of patients within 1 year, and in 50% to 60% of patients in 5 years. Breakthrough by the mutant occurs in 20% to 30% of patients. Few HBV-resistant mutants manifest when entecavir (¥1,038/d) is administered. The antiviral effect of entecavir is strong. Therefore, when HBV-DNA was detected, administration of entecavir was begun, and it seemed necessary to continue rituximab combination chemotherapy after the course of entecavir was completed. Thus, rituximab combination chemotherapy could be continued after entecavir administration was begun and when the serum HBV-DNA became negative. Regarding expense, the cost of testing for anti-HBs in Japan is ¥950, and the cost of testing for HBV-DNA is ¥2,900. Compared with the cost of prophylaxis with lamivudine (¥19,465/mo), the cost of testing for HBV-DNA (¥ 950/mo) is low. A large-scale prospective study on HBV-DNA monitoring to make an early diagnosis of HBV reactivation is necessary.
Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole.
Authors: J R Stratton, J L Ritchie
Journal: Circulation (1986)

Aspirin plus dipyridamole reduces platelet accumulation on short-term Dacron vascular grafts in man. To determine whether drug inhibition of platelet deposition is sustained on older grafts, we studied 18 men aged 41 to 87 years who had Dacron aortic bifurcation grafts in place a mean of 43.4 months (range 9.8 to 121.0) before and during short-term therapy with aspirin (325 mg tid) plus dipyridamole (75 mg tid). During both the baseline and drug studies, indium-111 (111In) platelet deposition was quantitated by two techniques, standard planar imaging performed at 24, 48, and 72 hr after injection of platelets and single photon emission computed tomographic imaging performed at 24 and 72 hr after injection. All analyses were performed in a blinded fashion. On both the planar and tomographic images, platelet accumulation on the graft was quantitated by a graft/blood ratio that compared activity in the graft to simultaneously collected whole blood 111In platelet activity. Aspirin plus dipyridamole reduced the tomographic graft/blood ratio at 24 hr (20.6 +/- 3.5 vs 17.3 +/- 2.5) (+/-SEM) and at 72 hr (29.0 +/- 4.8 vs 25.0 +/- 4.1) after injection of platelets (p = .02). Dacron vascular grafts. Similarly, the planar graft/blood ratio was reduced at 24 hr (2.7 +/- 0.5 vs 2.4 +/- 0.5), 48 hr (3.7 +/- 0.9 vs 3.1 +/- 0.7), and 72 hr (4.0 +/- 0.9 vs 3.6 +/- 0.8) (p = .04). We conclude that aspirin (325 mg tid) plus dipyridamole (75 mg tid) reduces platelet accumulation on long-term Dacron vascular grafts.
TCT-694 Acute Hemodynamic effects of the MitraClip(r) System. Focus on grade of MR, stroke volume, LA-, PA- and PCW- pressure. Analyzing 330 MitraClip procedures at the AK St. Georg, Hamburg
Authors: Thomas Thielsen, Christian Frerker, Felix Kreidel, Hannes Alessandrini, Marco Marzullo, Karl-Heinz Kuck, Ulrich Schaefer
Journal: Journal of the American College of Cardiology (2013)
Cimetidine Does Not Reduce Liver Blood Flow in Cirrhosis
Authors: J. Michael Henderson, Shakir Z. Ibrahim, William J. Millikan, Michael Santi, W. Dean Warren
Journal: Hepatology (2007)

Cimetidine has been shown to reduce liver blood flow, as measured by indocyanine green clearance, in normal subjects. Concern over the potential deleterious effects of such reduction in cirrhosis led to the measurement of blood flow in 14 cirrhotics receiving oral or intravenous cimetidine. Liver blood flow was measured by the clearance of galactose at steady state during infusion of 40 mg per min. In six patients receiving 300 mg cimetidine by mouth each 6 hr for 4 days, basal flow (1,019 ± 186 ml per min) was not significantly altered by cimetidine (1,087 ± 156 ml per min). Intravenous infusion of cimetidine (300 mg) did not significantly alter flow in five patients betwen the basal (1,096 ± 334 ml per min) and treatment periods (1,051 ± 383 ml per min). Hepatic extraction of galactose in three patients (82 ± 19%) was not significantly altered by cimetidine infusion (81 ± 13%). The failure to reduce liver blood flow with cimetidine in this population may be due to their diminished proportion of portal venous flow, or alternatively suggests that histamine is not an important modulator of flow via H2 receptors. At a clinical level, the use of cimetidine in this population can continue without fear of further reduction in liver blood flow.
β-Agonist Use and Death from Asthma
Authors: Samy Suissa
Journal: JAMA (1994)

<h3>To the Editor.</h3> —Mullen et al<sup>1</sup>apply a meta-analysis to five epidemiologic studies to conclude that the use of inhaled β-agonists by metered-dose inhaler is not associated with the risk of death from asthma. This conclusion is in direct contradiction to the conclusions of the four largest source studies used in their meta-analysis. We submit that this apparent inconsistency is the result of serious methodological flaws in the comparison of "did vs did not use β-agonist" employed in their meta-analysis. This comparison does not correspond to the contrasts designed or performed in the four principal source studies. The three New Zealand<sup>2-4</sup>studies were clearly comparing fenoterol with albuterol,<sup>2</sup>finding a higher risk for the former. Our study<sup>5</sup>focused on the dose-response analysis, which showed, for example, that in patients using any β-agonist the risk of asthma death for those using more than two canisters per month
More sweetness than light? A search for the causes of diabetic vasculopathy
Authors: Junsuke Igarashi, Thomas Michel
Journal: Journal of Clinical Investigation (2001)

Diabetes affects a large and growing number of individuals in industrialized countries worldwide; in the USA, over 16 million people suffer from diabetes, and even more show clinical features associated with prediabetic states (1). Vascular diseases represent an important cause of the morbidity and mortality associated with diabetes, and a very large body of experimental work has sought to elucidate the cellular and molecular mechanisms that underlie this important pathophysiological process. One of the hallmarks of diabetic vascular disease is endothelial dysfunction, which may be functionally defined as the failure of the vascular endothelium to subserve its normal role in vasodilation and/or vascular homeostasis.
Comparative responses to dobutamine and nitroprusside in patients with chronic low output cardiac failure.
Authors: C Berkowitz, L McKeever, R P Croke, W R Jacobs, H S Loeb, R M Gunnar
Journal: Circulation (1977)

The acute hemodynamic effects of dobutamine and nitroprusside were compared in 19 patients with low output cardiac failure. At dosage levels yielding similar increases in cardiac index (12 patients), nitroprusside resulted in significantly lower arterial systolic and wedge pressures and did not increase heart rate suggesting advantages over dobutamine when reduction in myocardial oxygen requirement or pulmonary congestion is a major goal. Systemic arterial mean and diastolic pressures were minimally changed with dobutamine, but fell significantly with nitroprusside suggesting advantages of dobutamine over nitroprusside in patients where hypotension could limit coronary blood flow or perfusion of other vital organs. Reduction in pulmonary arteriolar resistance occurred only with nitroprusside. Arterial hypoxemia developed in three patients during nitroprusside infusion suggesting the possibility of increased right-to-left intrapulmonary shunting resulting from a direct vasodilating effect of nitroprusside on pulmonary arteriole smooth muscle. Although both inotropic and vasodilator drugs can result in hemodynamic improvement when administered to patients with chronic low output cardiac failure, significant differences of potential clinical importance exist between these two modes of therapy.
Patency of Saphenous Aortocoronary-Bypass Grafts Demonstrated by Computed Tomography
Authors: Rogelio Moncada, Matias Salinas, Robert Churchill, Leon Love, Carlos Reynes, Terrence C. Demos, David Hale, Ronald Schreiber
Journal: New England Journal of Medicine (1980)

DURING the past 10 years aortocoronary bypass has been widely prescribed to treat angina pectoris. Dysfunction or closure of an aortocoronary-bypass graft is generally suggested by a patient's history, but few if any objective signs are derived from physical examination, electrocardiograms taken with patient at rest or under stress, or studies of regional myocardial perfusion with thallium–201.1 Definitive confirmation of graft closure or stenosis is obtained through postoperative selective angiography of the grafts in question. This invasive procedure is costly, requires hospitalization, and certainly carries some morbidity and mortality.A new technique, described by Lipton et al., 2 that uses computed . . .
Zinc, insulin, and the liver: a ménage à trois
Authors: Thomas V. O’Halloran, Melkam Kebede, Steven J. Philips, Alan D. Attie
Journal: Journal of Clinical Investigation (2013)

Insulin and Zn2+ enjoy a multivalent relationship. Zn2+ binds insulin in pancreatic β cells to form crystalline aggregates in dense core vesicles (DCVs), which are released in response to physiological signals such as increased blood glucose. This transition metal is an essential cofactor in insulin-degrading enzyme and several key Zn2+ finger transcription factors that are required for β cell development and insulin gene expression. Studies are increasingly revealing that fluctuations in Zn2+ concentration can mediate signaling events, including dynamic roles that extend beyond that of a static structural or catalytic cofactor. In this issue of the JCI, Tamaki et al. propose an additional function for Zn2+ in relation to insulin: regulation of insulin clearance from the bloodstream.
CLINICAL SIGNIFICANCE OF THE MINNESOTA MULTIPHASIC F SCALE EVALUATED IN EXPERIMENTAL NEUROSIS
Authors: JOSEF BROZEK, BURTRUM C. SCHIELE
Journal: American Journal of Psychiatry (1948)

Material is presented which indicates that an elevated F score on the MMPI in subjects with clinically established personality disturbances cannot necessarily be interpreted in the sense of questionable validity of the scores on the psychiatric scales of the inventory. The data were obtained in an experiment on the effects of prolonged semistarvation, in the course of which several individuals suffered a pronounced personality deterioration, reflected in the elevated scores on the neurotic and, in some cases, also on the psychotic scales. The analysis of the critical items of the F scale demonstrated that in the overwhelming majority the responses were in complete agreement with the clinical picture. In view of this evidence care must be taken not to interpret high F scores automatically as evidence of invalidity of the profile. We share the sentiments of Kazan and Sheinberg, who arrived at the same conclusion on the basis of purely clinical material, that the concept and use of the F scale simply as a validating score is questionable. It must be recognized that a high F score often may indicate the presence of a significant personality disturbance.